Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients

Abstract

The reporting proportion of PML was relatively higher in natalizumab followed by fingolimod, dimethyl fumarate and rituximab. Other characteristics of PML associated with DMDs, including the time to onset and differences in reporting among countries, are described.